Acne Vulgaris
📧 Sign up to get email alerts when something new happens for Acne Vulgaris.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-06-27FDA Approved: CLINDAMYCIN AND BENZOYL PEROXIDE — Original Application (Encube Ethicals, Inc.)
FDA approved an original generic application for a topical combination of clindamycin and benzoyl peroxide by Encube Ethicals, Inc.
-
CLINICAL_TRIALS trial_result · 2017-06-23Clinical Trial Update: A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris [Phase 1]
A Phase 1 trial update reports completion of a bioavailability study comparing tazarotene 0.1% foam and tazarotene 0.1% gel in subjects with…
-
CLINICAL_TRIALS trial_result · 2017-06-22Clinical Trial Update: Bioequivalence Minocycline Bioequivalence [Phase 1]
Phase 1 trial evaluating the bioequivalence of minocycline formulations for acne has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ [Phase 4]
Phase 4 trial evaluating MAXCLARITY II versus PROACTIV for acne vulgaris has completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers [Phase 1]
This Phase 1 trial evaluates the skin irritation potential of tazarotene foam in healthy volunteers, related to acne treatment.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers [Phase 1]
A Phase 1 study evaluating whether applying tazarotene foam to the skin and exposing it to light causes a reaction in healthy volunteers.
-
FDA approval · 2017-06-17FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Claravis (isotretinoin) from Teva Pharmaceuticals USA, Inc., indicating an update related to…
-
FDA approval · 2017-06-17FDA Approved: AMNESTEEM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental ANDA for AMNESTEEM (isotretinoin) from Mylan Pharmaceuticals. This approval confirms a generic version of the br…
-
FDA approval · 2017-06-17FDA Approved: ISOTRETINOIN — Supplemental Application (Mayne Pharma)
FDA approved a supplemental application for isotretinoin submitted by Mayne Pharma.
-
FDA label_change · 2017-06-17FDA Approved: ABSORICA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ABSORICA (isotretinoin) from Sun Pharmaceutical Industries, Inc., resulting in updates to the la…
-
FDA approval · 2017-06-17FDA Approved: CLARAVIS — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for CLARAVIS (isotretinoin) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2017-06-17FDA Approved: ZENATANE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Zenatane (isotretinoin) with BluePoint Laboratories as the manufacturer.
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne [Phase 1]
Phase 1, randomized, open-label study assessing the bioavailability of three clindamycin/benzoyl peroxide gel formulations for acne vulgaris…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers [Phase 1]
A Phase 1 trial completed to assess the contact sensitization potential of tazarotene foam on the skin in healthy volunteers. The study is a…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers. [Phase 1]
A Phase 1 study evaluated whether tazarotene foam could provoke an allergic reaction when applied to the skin and exposed to light in health…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Cutaneous JAK in Vitiligo and Acne Vulgaris.
This entry notes an ongoing or planned study investigating cutaneous JAK inhibitors for vitiligo and acne vulgaris, with no status or result…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Polymorphism of Extrapituitary Promoter of PRL Gene and Relationships With Serum Prolactin Levels in Acne Vulgaris.
This clinical trial investigates polymorphisms in the extrapituitary promoter of the prolactin (PRL) gene and their relationship to serum pr…
-
CLINICAL_TRIALS trial_result · 2017-06-12Clinical Trial Update: A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition [Phase 1]
This Phase 1 trial completed a bioequivalence comparison of isotretinoin formulations in healthy male volunteers under fed conditions.
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris [Phase 4]
A Phase 4 trial comparing Duac Gel with Differin Gel in mild-to-moderate acne vulgaris has completed. The study evaluates the efficacy and s…
-
FDA approval · 2017-05-19FDA Approved: DIFFERIN — Supplemental Application (Galderma Laboratories, L.P.)
FDA approved a supplemental application for DIFFERIN (adapalene) submitted by Galderma Laboratories, L.P.
-
CLINICAL_TRIALS trial_result · 2017-05-09Clinical Trial Update: Study to Investigate the Irritation Potential of GSK1940029 Gel [Phase 1]
A Phase 1 trial completed to assess the irritation potential of GSK1940029 Gel in acne vulgaris patients.
-
CLINICAL_TRIALS trial_result · 2017-05-09Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029 [Phase 1]
Phase 1 trial update evaluating safety, tolerability, and pharmacokinetics of single and 14-day repeat topical application of the investigat…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris [Phase 1]
Phase 1 clinical trial comparing clindamycin phosphate and benzoyl peroxide gel to Acanya gel and to a vehicle control for acne vulgaris.
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris [Phase 1]
This document reports the completion of a Phase 1 clinical trial evaluating a test treatment versus Aczone 5% and placebo for acne vulgaris.
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris [Phase 1]
A completed Phase 1 trial comparing a test compound, Aczone 7.5% topical, and placebo for acne vulgaris.